169 related articles for article (PubMed ID: 12569556)
1. Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids.
Sasagawa T; Rose RC; Azar KK; Sakai A; Inoue M
Int J Cancer; 2003 Apr; 104(3):328-35. PubMed ID: 12569556
[TBL] [Abstract][Full Text] [Related]
2. Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions.
Sasagawa T; Inoue M; Lehtinen M; Zhang W; Gschmeissner SE; Hajibagheri MA; Finch J; Crawford L
Clin Diagn Lab Immunol; 1996 Jul; 3(4):403-10. PubMed ID: 8807204
[TBL] [Abstract][Full Text] [Related]
3. Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA.
Wang Z; Hansson BG; Forslund O; Dillner L; Sapp M; Schiller JT; Bjerre B; Dillner J
J Clin Microbiol; 1996 Dec; 34(12):3056-62. PubMed ID: 8940448
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions.
Sasagawa T; Yamazaki H; Dong YZ; Satake S; Tateno M; Inoue M
Int J Cancer; 1998 Feb; 75(4):529-35. PubMed ID: 9466652
[TBL] [Abstract][Full Text] [Related]
5. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16.
Bontkes HJ; de Gruijl TD; Walboomers JM; Schiller JT; Dillner J; Helmerhorst TJ; Verheijen RH; Scheper RJ; Meijer CJ
J Gen Virol; 1999 Feb; 80 ( Pt 2)():409-417. PubMed ID: 10073701
[TBL] [Abstract][Full Text] [Related]
6. Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes.
Costa AP; Giraldo PC; Cobucci RN; Consolaro ML; Souza RP; Canário LB; Machado PR; Randall Martins R; Vieira Baptista P; Jr JE; Gonçalves AK
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2799-2804. PubMed ID: 32986383
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of human papillomavirus genotypes, and mucosal IgA anti-viral responses in women with cervical ectopy.
Monroy OL; Aguilar C; Lizano M; Cruz-Talonia F; Cruz RM; Rocha-Zavaleta L
J Clin Virol; 2010 Jan; 47(1):43-8. PubMed ID: 19906557
[TBL] [Abstract][Full Text] [Related]
8. Correlates of cervical mucosal antibodies to human papillomavirus 16: results from a case control study.
Bierl C; Karem K; Poon AC; Swan D; Tortolero-Luna G; Follen M; Wideroff L; Unger ER; Reeves WC
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S262-8. PubMed ID: 16229879
[TBL] [Abstract][Full Text] [Related]
9. Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions.
Strickler HD; Schiffman MH; Eklund C; Glass AG; Scott DR; Sherman ME; Wacholder S; Kurman RJ; Manos MM; Schiller JT; Dillner J
Cancer Epidemiol Biomarkers Prev; 1997 Mar; 6(3):183-8. PubMed ID: 9138661
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia.
de Gruijl TD; Bontkes HJ; Walboomers JM; Schiller JT; Stukart MJ; Groot BS; Chabaud MM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
J Natl Cancer Inst; 1997 May; 89(9):630-8. PubMed ID: 9150187
[TBL] [Abstract][Full Text] [Related]
11. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens.
Elfgren K; Bistoletti P; Dillner L; Walboomers JM; Meijer CJ; Dillner J
Am J Obstet Gynecol; 1996 Mar; 174(3):937-42. PubMed ID: 8633673
[TBL] [Abstract][Full Text] [Related]
12. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.
de Gruijl TD; Bontkes HJ; Walboomers JM; Coursaget P; Stukart MJ; Dupuy C; Kueter E; Verheijen RH; Helmerhorst TJ; Duggan-Keen MF; Stern PL; Meijer CJ; Scheper RJ
J Gen Virol; 1999 Feb; 80 ( Pt 2)():399-408. PubMed ID: 10073700
[TBL] [Abstract][Full Text] [Related]
13. Antibody levels against galactosyl (alpha1 --> 3) galactose epitopes in cervical mucus from patients with human papillomavirus infection.
Hernàndez DE; Cohen A; Fisher D; Correnti M; Harner R
Gynecol Oncol; 2002 Mar; 84(3):374-7. PubMed ID: 11855872
[TBL] [Abstract][Full Text] [Related]
14. Analysis of IgG reactivity against Human Papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasia indicates an association with clearance of viral infection: results of a prospective study.
de Gruijl TD; Bontkes HJ; Walboomers JM; Stukart MJ; Robbesom AA; von Blomberg-van der Flier BM; Herbrink P; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
Int J Cancer; 1996 Dec; 68(6):731-8. PubMed ID: 8980175
[TBL] [Abstract][Full Text] [Related]
15. Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions.
Rocha-Zavaleta L; Ambrosio JP; Mora-Garcia ML; Cruz-Talonia F; Hernandez-Montes J; Weiss-Steider B; Ortiz-Navarrete V; Monroy-Garcia A
J Gen Virol; 2004 Sep; 85(Pt 9):2643-2650. PubMed ID: 15302958
[TBL] [Abstract][Full Text] [Related]
16. Detection of autoantibodies to survivin in cervical mucus from patients with human papillomavirus-associated cervical cancer and precursor lesions.
Jimenez LG; Aguilar MC; Monroy OL; Cruz-Talonia F; Cruz RM; Huitron C; Rocha-Zavaleta L
Autoimmunity; 2007 Feb; 40(1):66-72. PubMed ID: 17364499
[TBL] [Abstract][Full Text] [Related]
17. Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia.
Marais DJ; Best JM; Rose RC; Keating P; Soeters R; Denny L; Dehaeck CM; Nevin J; Kay P; Passmore JA; Williamson AL
J Med Virol; 2001 Sep; 65(1):149-54. PubMed ID: 11505457
[TBL] [Abstract][Full Text] [Related]
18. Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women.
Petter A; Heim K; Guger M; Ciresa-Kö Nig A; Christensen N; Sarcletti M; Wieland U; Pfister H; Zangerle R; Höpfl R
J Gen Virol; 2000 Mar; 81(Pt 3):701-8. PubMed ID: 10675407
[TBL] [Abstract][Full Text] [Related]
19. Seric and local antibodies against a synthetic peptide of HPV16.
Dreyfus M; Baldauf JJ; Ritter J; Obert G
Eur J Obstet Gynecol Reprod Biol; 1995 Apr; 59(2):187-91. PubMed ID: 7657014
[TBL] [Abstract][Full Text] [Related]
20. IgG antibodies to human papillomavirus 16, 52, 58, and 6 L1 capsids: case-control study of cervical intraepithelial neoplasia in Japan.
Matsumoto K; Yoshikawa H; Yasugi T; Nakagawa S; Kawana K; Takeoka A; Yaegashi N; Iwasaka T; Kanazawa K; Taketani Y; Kanda T
J Med Virol; 2003 Mar; 69(3):441-6. PubMed ID: 12526056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
